

PEI Pharmacare Bulletin

Issue (2019 - 9)

October 16, 2019

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY (EFFECTIVE DATE: October 28, 2019)

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN	MFR
Tenofovir alafenamide/Emtricitabine/Bictegravir	Biktarvy	25mg/200mg/50mg	Tablet	02478579	GIL
Criteria	Open Benefit				
Program Eligibility	AIDS/HIV				

CRITERIA CHANGE

Effective immediately, as a result of serious adverse reactions recently reported through Health Canada (resulting in an updated product monograph) with the use of alemtuzumab (Lemtrada®), special authorization criteria has been updated as identified below.

alemtuzumab	Lemtrada	12mg/1.2ml	Injection	02418320	AVN
Criteria	For the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to two other disease-modifying therapies (DMTs), except for when any other DMT is contraindicated or unsuitable, if the following clinical criteria are met: <ul style="list-style-type: none"> • At least two attacks(first episode or relapse) in the previous two years, with at least one attack in the previous year; • At least one relapse while on at least six months of two different disease modifying therapies within the last 10 years; except for when any other DMT is contraindicated or unsuitable, • An Expanded Disability Status Scale (EDSS) score of five (5) or less; • Prescribed by a specialist with experience in the treatment of multiple sclerosis 				
Program Eligibility	High Cost Drug Program, Catastrophic Drug Program				